Treatment outcome and toxicity after salvage 125-I implantation for prostate cancer recurrences after primary 125-I implantation and external beam radiotherapy

Moman, Maaike R.; Poel, Henk G. van der; Battermann, Jan J.; Moerland, Marinus A.; Vulpen, Marco van

doi:10.1016/j.brachy.2009.06.007

Cited by 68 publications

(36 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Salvage whole-gland treatments with surgery or brachytherapy for intra-prostatic failure are feasible with good oncological outcomes, but some patients may experience harmful late toxicity [5,7]. A focal salvage approach, if feasible, could decrease the rates of such sequelae [6].…”

Section: Discussionmentioning

confidence: 99%

Cold spot mapping inferred from MRI at time of failure predicts biopsy-proven local failure after permanent seed brachytherapy in prostate cancer patients: Implications for focal salvage brachytherapy

Créhange

Krishnamurthy

Cunha

et al. 2013

Radiotherapy and Oncology

View full text Add to dashboard Cite

Background and purpose To establish a method to evaluate dosimetry at the time of primary prostate permanent implant (pPPI) using MRI of the shrunken prostate at the time of failure (tf). To compare cold spot mapping with sextant-biopsy mapping at tf. Material and methods Twenty-four patients were referred for biopsy-proven local failure (LF) after pPPI. Multiparametric MRI and combined-sextant biopsy with a central review of the pathology at tf were systematically performed. A model of the shrinking pattern was defined as a Volumetric Change Factor (VCF) as a function of time from time of pPPI (t0). An isotropic expansion to both prostate volume (PV) and seed position (SP) coordinates determined at tf was performed using a validated algorithm using the VCF. Results pPPI CT-based evaluation (at 4 weeks) vs. MR-based evaluation: Mean D90% was 145.23 ± 19.16 Gy [100.0–167.5] vs. 85.28 ± 27.36 Gy [39–139] (p = 0.001), respectively. Mean V100% was 91.6 ± 7.9% [70–100%] vs. 73.1 ± 13.8% [55–98%] (p = 0.0006), respectively. Seventy-seven per cent of the pathologically positive sextants were classified as cold. Conclusions Patients with biopsy-proven LF had poorer implantation quality when evaluated by MRI several years after implantation. There is a strong relationship between microscopic involvement at tf and cold spots.

show abstract

Section: Discussionmentioning

confidence: 99%

Cold spot mapping inferred from MRI at time of failure predicts biopsy-proven local failure after permanent seed brachytherapy in prostate cancer patients: Implications for focal salvage brachytherapy

Créhange

Krishnamurthy

Cunha

et al. 2013

Radiotherapy and Oncology

View full text Add to dashboard Cite

show abstract

“…Other series have provided risk factors for biochemical failure with small groups of whole-gland salvage LDR I-125/Pd-103 and HDR Ir-192-brachytherapy patients and even focal salvage approaches (directed locally at the recurrence) [10][11][12][13][24][25][26][27][28][29][30] . Only a few of the whole-gland salvage brachytherapy studies provide multivariable modelling, with often limited events, categorisation of predictor variables and insufficient description of handling missing data, leading to imprecise estimates [11][12][13]26 .…”

Section: Discussionmentioning

confidence: 99%

“…Only a few of the whole-gland salvage brachytherapy studies provide multivariable modelling, with often limited events, categorisation of predictor variables and insufficient description of handling missing data, leading to imprecise estimates [11][12][13]26 . However, there is no data on predictive factors for survival (PCaSS and OS).…”

Section: Discussionmentioning

confidence: 99%

“…Risk factors for failure and mortality for salvage brachytherapy have not been comprehensively defined, because of small series with often limited events 5,9,10 . A few series have defined pre-salvage PSA, PSA-doubling time (PSADT) and time-to-relapse after primary therapy as possible predictors of biochemical failure after salvage brachytherapy [11][12][13] . Although biochemical failure often precedes the development of distant metastases and death 1 , no predictive factors for survival have as of yet been identified.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Multivariable model development and internal validation for prostate cancer specific survival and overall survival after whole-gland salvage Iodine-125 prostate brachytherapy

Peters

Zyp

Moerland

et al. 2016

Radiotherapy and Oncology

Self Cite

View full text Add to dashboard Cite

Background: Whole-gland salvage Iodine-125-brachytherapy is a potentially curative treatment strategy for localised prostate cancer (PCa) recurrences after radiotherapy. Prognostic factors influencing PCa-specific and overall survival (PCaSS & OS) are not known. The objective of this study was to develop a multivariable, internally validated prognostic model for survival after whole-gland salvage I-125-brachytherapy.

show abstract

“…Some patients have showed genitourinary and gastrointestinal adverse events of grade 3 or greater, but the incidence rate was acceptable. Some reports involved prescription of a full dose (145 Gy), while the prescribed dose was reduced according to other reports [1–7]. There is not a standard prescribed dose and the pros and cons of adjuvant hormonal therapy are not established.…”

Section: Discussionmentioning

confidence: 99%

Salvage brachytherapy for seminal vesicle recurrence after initial brachytherapy for prostate cancer: a case report

et al. 2014

View full text Add to dashboard Cite

BackgroundTo report the efficacy and safety of salvage brachytherapy for seminal vesicle recurrence after initial brachytherapy in a patient with prostate cancer. As far as we know, this is a first report of salvage brachytherapy for seminal vesicle recurrence in Japan.Case presentationA 70-year-old Japanese man with low-risk prostate cancer received low-dose-rate brachytherapy. Forty-two months after the seed implantation, he showed biochemical recurrence based on the nadir + 2 ng/mL definition. The prostate specific antigen (PSA) level was 5.11 ng/mL at 58 months after seed implantation. A saturation biopsy of the prostate showed no recurrence. Systemic screening also showed no distant metastases. However, T2-weighted magnetic resonance imaging (MRI) demonstrated a low intensity area at the base of the right seminal vesicle, which was strongly suggestive of recurrence. Sixty months after the initial therapy, a seminal vesicle biopsy confirmed recurrence with a Gleason score of 4 + 3 before salvage brachytherapy was performed. The prescribed dose was 145 Gy, the same as the dose of the initial therapy. One month later, the PSA level had rapidly declined to 0.898 ng/mL without androgen deprivation therapy. Ten months after the salvage brachytherapy, the PSA level reached 0.078 ng/mL. No adverse events were seen during the follow-up period.ConclusionsWe experienced a patient who was successfully treated with salvage brachytherapy for seminal vesicle recurrence. Salvage brachytherapy is one of the promising therapeutic options for recurrence after initial brachytherapy.

show abstract

Treatment outcome and toxicity after salvage 125-I implantation for prostate cancer recurrences after primary 125-I implantation and external beam radiotherapy

Cited by 68 publications

References 19 publications

Cold spot mapping inferred from MRI at time of failure predicts biopsy-proven local failure after permanent seed brachytherapy in prostate cancer patients: Implications for focal salvage brachytherapy

Cold spot mapping inferred from MRI at time of failure predicts biopsy-proven local failure after permanent seed brachytherapy in prostate cancer patients: Implications for focal salvage brachytherapy

Multivariable model development and internal validation for prostate cancer specific survival and overall survival after whole-gland salvage Iodine-125 prostate brachytherapy

Salvage brachytherapy for seminal vesicle recurrence after initial brachytherapy for prostate cancer: a case report

Contact Info

Product

Resources

About